• Dealmakers Predict Banner Year as Biopharma M&A Momentum Builds

    Jan 23 | Bio-IT World | The mood at this year's J.P. Morgan Healthcare Conference signals a dramatic shift for biopharma dealmaking, with industry leaders projecting 2026 could eclipse last year's surging merger and acquisition activity. During an Endpoints News panel discussion, senior executives from AbbVie, Amgen, and Merck expressed confidence that favorable market conditions and breakthrough science are converging to create what one panelist called "a renaissance moment" for the sector. More

  • Improved Drug Safety Needs Better Data Before AI

    Jan 23 | Bio-IT World | Applying artificial intelligence (AI) to fragmented and incomplete safety data cannot fill the gap left when the right information has not been captured during initial patient adverse event reporting. And yet, software vendors position the technology as a quick fix to safety data complexity. Although AI definitely has a role to play, it would be far better to use it to refine the data capture process. More

  • AI in Pharma: Progress Made, But Data Challenges Persist

    Jan 20 | Bio-IT World | The pharmaceutical industry’s approach to artificial intelligence is maturing, with companies increasingly focused on innovation rather than mere efficiency gains. However, significant hurdles around data quality and workforce training continue to impede progress. More

  • 10x Genomics Positions Spatial Biology as Center Stage as AI Fuels New Wave of Customer Demand

    Jan 14 | Bio-IT World | At the 44th Annual J.P. Morgan Healthcare Conference, 10x Genomics announced a strong ending to 2025. With great anticipation for 2026, 10x Genomics remains centered on their mission on accelerating understanding of biology to advance human health, particularly in the single-cell and spatial biology areas. More

  • Illumina at JPM 2026: Strong Q4, Clinical Growth, and BioInsight Launch

    Jan 13 | Bio-IT World | Jacob Thaysen returned to the J.P. Morgan Healthcare Conference stage Tuesday with a message of momentum: Illumina is back to growth, and clinical sequencing is driving the train. In his third annual presentation as CEO, Thaysen unveiled preliminary fourth quarter results that exceeded expectations and introduced BioInsight, a new business unit aimed at accelerating drug discovery through AI-powered biological insights. More

  • PacBio at JPM 2026: Clinical Momentum and SPRQ-Nx Economics

    Jan 13 | Bio-IT World | PacBio president Christian Henry presented at the 44th Annual J.P. Morgan Healthcare Conference with strong fourth quarter growth, breakthrough clinical adoption, and economics that position long-read sequencing as competitive with short reads. More

  • Oxford Nanopore at JPM 2026: Passing the Baton on a 20-Year Journey

    Jan 12 | Bio-IT World | Gordon Sanghera, CEO, presented on behalf of Oxford Nanopore Technologies at the 44th Annual J.P. Morgan Healthcare Conference this week in San Francisco. In what he described as his final appearance at JPM as CEO, Sanghera reflected on 20 years of building a company around single-molecule electronic sensing while outlining a growth trajectory that saw the company exceed expectations in 2025. More

  • NVIDIA Bets Big on AI-Driven Drug Discovery, Physical AI, and a $1 Billion Eli Lilly Partnership

    Jan 12 | Bio-IT World | NVIDIA is making a massive push into healthcare and life sciences, announcing a landmark five-year, $1 billion strategic partnership with pharmaceutical giant Eli Lilly alongside major expansions of its biological AI platform at the 2026 J.P. Morgan Healthcare Conference. More

  • TechBio Survey Shows a Mixed Industry Outlook, Claude Gaining Ground, More Machine Learning

    Jan 09 | Bio-IT World | The Bits in Bio Slack-first community has released its fourth annual State of TechBio survey results. Year over year findings include a jump in Claude usage, an increase in daily machine learning work, and a serious cooling of the “Very bullish" sentiment across the broader biotech market. More

  • Systems Biology Map for Advancing the Translation of Extracellular Vesicles

    Jan 07 | Bio-IT World | Extracellular vesicles (EVs) are the master communicators of multicellular life, key in orchestrating the complex signaling networks that define physiology. A new multiomics study has now revealed their molecular cargo via EVMap, a high-resolution blueprint of the proteins and lipids in human circulating EVs providing a practical pathway forward across basic, translational and clinical applications. More
View more articles
Bio IT World Lead Gen

 
Industry-spotlight

Riffyn’s pioneering cloud system, Riffyn Nexus, delivers 2X faster development cycles and 4X productivity gains to the world’s most advanced scientific R&D organizations. Its process-centric experiment design, data capture, and data analytics overcome the limitations of ELN and LIMS systems. Its adaptive data integration engine delivers results that are always ready for machine learning.
Read more here!

Industry-spotlight
Trends from the Trenches

Bio-IT World’s Trends from the Trenches podcast delivers your insider’s look at the science, technology, and executive trends driving the life sciences through conversations with industry leaders. BioTeam co-founder Stan Gloss brings years of industry experience in science, data, and technology to conversations exploring what is driving data and discovery, and what’s coming next.
Listen today!